GÖKHAN TEMELTAŞ, FUNDA KOSOVA, TALHA MÜEZZİNOĞLU, Zeki ARI

Adipocytokine levels in benign prostate hyperplasia and prostate cancer patients

The occurrence of prostate cancer in men is one of the most common types of cancer. Recent studies have found important links between cancer and adipocytokines. Adipocytokines are thought to be factors in the occurrence of a variety of diseases. In addition, adipocytokines studies in cancer patients have shown that these hormones may have an effect in the formation of cancer. The objective of this study was to evaluate the relationship between adiponectin, resistin, and leptin levels in BHP and prostate cancer patients. The study was conducted between September 2012 and April 2013 at the Department of Medical Biochemistry and the Department of Urology. Blood samples were collected from 20 people in the same age range who had been diagnosed by examination and biopsy as having BHP (benign prostatic patients) and prostate cancer patients who had not been operated on. Leptin, adiponectin, resistin, and human serum levels were measured using ELISA kit. In the prostate cancer group, serum adiponectin and resistin levels were significantly lower than in the BHP group. However, serum leptin levels in the prostate cancer group were not significantly different from those in the BHP group. This information and our own findings show that adiponectin and resistin, which are from the adipocytokine family, may play an important role in the progression of prostate cancer, and thus it may be possible to use them as diagnostic markers. Therefore, similar studies should be considered with a greater number of patients at different stages

PDF

___

1. Akdaş A, Çevik I. BHP- Benign Prostat Hiperplazisi. Hekimler Yayın Birliği. 1996;27-37.

2. Rcquıer D. Respiration uncoupling and metabolism in the control of energy expenditure. Proc Nutr Soc. 2005;64(1):47-2.

3. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307(5708):426-30.

4. Zhao Y, Sun R, You L, Gao C, Tian Z. Expression of leptin receptors and response to leptin stimulation of human natural killer cell lines. Biochem Biophys Res Commun. 2003;300(2):247-2.

5. Caldefie-Chezet F, Poulin A, Tridon A, Sion B, Vasson MP.. Leptin: a potential regulator of polymorphonuclear neutrophil bactericidal action? J Leukoc Biol. 2001;69(3):414-8.

6. Galili O, Versari D, Sattler KJ, Olson ML, Mannheim D, McConnell JP, Chade AR, Lerman LO, Lerman A. Early Experimental Obesity Is Associated with Coronary Endothelial Dysfunction and Oxidative Stress. Am J Physiol Heart Circ Physiol. 2007;292(2):904-1.

7. Koerner A, Kratzsch J, Kiess W. Adipocytokines: leptin the classical, resistin the controversical, adiponectin the promising, and more to come. Best Pract Res Clin Endocrinol Metab. 2005;19(4):525-46.

8. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino Y, Okutomi K, Horie M, Takeda S, Aoyama T, Funahashi T, Matsuzawa Y. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med. 2002;8(7):731-7.

9. Wasim H, Al-Daghri NM, Chetty R, McTernan PG, Barnett AH, Kumar S. Relationship of serum adiponectin and resistin to glucose intolerance and fat topography in South-Asians. Cardiovasc Diabetol. 2006;2:5-0.

10. Palomer X, Pérez A, Blanco-Vaca F. Adiponectin: a new link between obesity, insulin resistance and cardiovascular disease. Med Clin (Barc). 2005;124(10):388-5.

11. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307(5708):426-0.

12. Bray Ga. The underlying basis for obesity relationship to cancer. J Nutr. 2002;132(11):3451-5.

13. Garofalo C, Surmacz E. Leptin and cancer. J Cell Physiol. 2005;207(1):12-22.

14. Drake RL, Wayne V, Mitchell, AWM, Gray H. Gray's Anatomy for Students, 2nd edition. Churchill Livingstone/Elsevier, Philadelphia, 2010;1821-65.

15. Standring S. Gray’s Anatomy. The Anatomical Basis of Clinical Practise, 38th edition, Churchill Livingstone. 2005;760-80.

16. Gleason DF. Histologic gradeing of prostate cancer. A perspective Hum Pathol. 1992;23(3):273-9.

17. Chu TM, Kawinski E, Hibi N, Croghan G, Wiley J, Killian CS, Corral D. Prostate specific antigen domain of human prostate specific antigen identified with monoclonal antibodies. J Urol. 1989;141:152-8.

18. K.M. Nieman, I.L. Romero, B. Van Houten, E. Lengyel, Adipose tissue and adipocytes support tumorigenesis and metastasis, Biochim Biophys Acta. 2013;1831(10):1533-41.

19. Wang YY, Lehuédé C, Laurent V, Dirat B, Dauvillier S, Bochet L, Le Gonidec S, Escourrou G, Valet P, Muller C. Adiopose tissue and breast epithelial cells a dangerous dynamic duo in breast cancer. Cancer Lett. 2012;324(2):142-53.

20. Toren P, Venkateswaran V. Periprostatic adipose tissue and prostate cancer progression: new insights into the tumor microenvironment. Clin Genitourin Cancer. 2014;12(1):21-6.

21. Nakajima TE, Yamada Y, Hamano T, Furuta K, Gotoda T, Katai H, Kato K, Hamaguchi T, Shimada Y. Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer. J Gastroenterol. 2009;44(7):685–0.

22. Fukumoto J, Otake T, Tajima O, Tabata S, Abe H, Mizoue T, Ohnaka K, Kono S. Adiponectin and colorectal adenomas: self defense forces health study. Cancer Sci. 2008;99(4):781-6.

23. Kumor A, Daniel P, Pietruczuk M, Małecka-Panas E. Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patients. Int J Colorectal Dis. 2009;24(3):275-1.

24. Finley DS, Calvert VS, Inokuchi J, Lau A, Narula N, Petricoin EF, Zaldivar F, Santos R, Tyson DR, Ornstein DK. Periprostatic adipose tissue as a modulator of prostate cancer aggressiveness. J Urol. 2009;182(4):1621–7.

25. Nakajima TE, Yamada Y, Hamano T, Furuta K, Matsuda T, Fujita S, Kato K, Hamaguchi T, Shimada Y. Adipocytokines as new promising markers of colorectal tumors: Adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci. 2010;101(5):1286-1.

26. Markowska A, Malendowicz K, Drews K. The role of leptin in breast cancer. Eur J Gynaecol Oncol. 2004;25(2):192–4.

27. Hardwick JC,Van Den Brink GR, Offerhaus GJ, Van Deventer SJ, Peppelenbosch MP. Leptin is a growth factor for colonic epithelial cells. Gastroenterology. 2001;121(1):79–90.

28. Emilsson V, Liu YL, Cawthorne MA, Morton NM, Davenport M. Expression of the functional leptin receptor mRNA in pancreatic islet and direct inhibitory action of leptin on insulin secretion. Diabetes. 1997;46(2):313-6.

29. Briscoe CP, Hanif S, Arch JR, Tadayyon M. Leptin receptor longform signaling in a human liver cell line. Cytokine. 2001;14(4): 225-9.

30. Huang L, Li C. Leptin: a multifunctional hormone, Cell Res. 2000;10(2):81-2

31. Housa D, Housová J, Vernerová Z, Haluzík M. Adipocytokines and Cancer. Physiol Res. 2006;55(3):233-4.

32. Mantzoros CS, Bolhke K, Moschos S, Cramer DW. Leptin in relation to carcinoma in situ of the breast: a study of pre-menopausal cases and controls. Int J Cancer. 1999;80(4):523-6.

33. Freedland SJ. Obesity and prostate cancer: a growing problem. Clin Cancer Res. 2005;11(19 Pt 1):6763–6.

34. Freedland SJ, Sokoll LJ, Mangold LA, Bruzek DJ, Mohr P, Yiu SK, Epstein JI, Partin AW: Serum leptin and pathological findings at the time of radical prostatectomy. J Urol. 2005;173(3):773–6.

35. Nazian SJ, Cameron DF: Temporal relation between leptin and various indices of sexual maturation in the male rat. J Androl. 1999;20(4):487- 91.

36. Kosova F, , Sepici-Dincel A, Engin A, Memiş L, Koca C, Altan N. The thyroid hormone mediated effects of insulin on serum leptin levels of diabetic rats. Endocrine. 2008;33(3):317-2.

37. Akıncı M, Kosova F, Cetin B, Aslan S, Ari Z, Cetin A. Leptin levels in thyroid cancer. Asian J Surg. 2009;32(4):216-3.

38. Kosova F, Coskun T, Kaya Y, Kara E, Ari Z. Adipocytokine levels of colon cancer patients before and after treatment. Bratisl Lek Listy. 2013;114(7):394-7.

39. Zhang Q, Sun LJ, Yang ZG, Zhang GM, Huo RC. Influence of adipocytokines in periprostatic adipose tissue on prostate cancer aggressiveness. Cytokine. 2016;85:148-56.

40. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning andexpression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript1). Biochem Biophys Res Commun. 1996;221(2):286-9.

41. Nakano Y, Tobe T, Choi-Miura NH, Mazda T, Tomita M. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem. 1996;120(4):803-2.

42. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257(1):79-3.

43. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, Kihara S, Funahashi T, Tenner AJ, Tomiyama Y, Matsuzawa Y. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood. 2000;96(5):1723–2.

44. Matsubara M, Maruoka S, Katayose S. Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. Eur J Endocrinol. 2002;147(2):173-80.

45. Rose DP, Gilhooly EM, Nixon DW. Adverse effects of obesity on breast cancer prognosis, and the biological actions of leptin. Int J Oncol. 2002;21(6):1285-2.

46. Burton A, Martin RM, Holly J, Lane JA, Donovan JL, Hamdy FC, Neal DE, Tilling K. Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: the ProtecT study. Cancer Causes Control. 2013;24(2):323–4.

47. Izadi V, Farabad E, Azadbakht L. Serum Adiponectin Level and Different Kinds of Cancer: A Review of Recent Evidence. ISSRN Oncol. 2012;2012:982769.

48. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature. 2001;409(6818):307–12.

49. Kim HJ, Lee YS, Won EH, Chang IH, Kim TH, Park ES, Kim MK, Kim W, Myung SC. Expression of resistin in the prostate and its stimulatory effect on prostate cancer cell proliferation. BJU Int. 2011;108(2 Pt 2):E77–E83.

50. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation. 2005;111(7):932-9.

51. Lawlor MA, Alessi DR. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci. 2001;114(16):2903-10.

52. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev. 1999;13(22):2905-27.

53. Chung S, Furihata M, Tamura K. Uemura M, Daigo Y, Nasu Y, Miki T, Shuin T, Fujioka T, Nakamura Y, Nakagawa H. Overexpressing PK1B in prostate cancer promotes its aggressiveness by linking between PKA and Akt pathways. Oncogene. 2009;28(32):2849-59.

54. Li R, Dai H, Wheeler TM, Sayeeduddin M, Scardino PT, Frolov A, Ayala GE. Prognostic value of Akt-1 in human prostate cancer: a computerized quantitative assessment with quantum dot technology. Clin Cancer Res 2009;15(10):3568–73.

55. Sarker D, Reid AH, Yap TA, de Bono JS. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res. 2009;15(15):4799-805.

56. Shalev A, Patterson NB, Hirshberg B, Rother KI, Harlan DM. Resistin serum levels in type 1 diabetes pre- and postislet transplantation. Metabolism. 2004;53(4):403-4.

57. Greco F, Hoda M.R, Wagner S, Reichelt O, Inferrera A, Fischer K, Fornara P, Adipocytokine: a new family of inflammatory and immunologic markers of invasiveness in major urologic surgery. Eur Urol. 2010;58(5):781-7.